<DOC>
	<DOCNO>NCT01802411</DOCNO>
	<brief_summary>The purpose study examine safety efficacy liposome bupivacaine intercostal nerve block subject undergoing posterolateral thoracotomy .</brief_summary>
	<brief_title>Intercostal Nerve Block With Liposome Bupivacaine Subjects Undergoing Posterolateral Thoracotomy</brief_title>
	<detailed_description />
	<mesh_term>Pain , Postoperative</mesh_term>
	<mesh_term>Bupivacaine</mesh_term>
	<criteria>Male female , ≥18 year age . Scheduled undergo thoracotomy least 3 inch ( 7.6 cm ) intercostal incisional length require insertion interrib spreader/retractor primary thoracic noninfectious indication general anesthesia . American Society Anesthesiologists ( ASA ) Physical Status 1 3 . Able provide inform consent , adhere study visit schedule , complete study assessment . Able demonstrate sensory function exhibit sensitivity cold one dermatome area study drug administer . Currently pregnant , nursing , plan become pregnant study within 1 month study drug administration . Female subject must surgically sterile , least 2 year menopausal , use acceptable method birth control . If childbearing potential , must document negative pregnancy test within 24 hour surgery . Any planned pleurodesis part surgical procedure . Use following medication within time specify surgery : longacting opioid medication , nonsteroidal antiinflammatory drug ( NSAID ) , aspirin ( except lowdose aspirin use cardioprotection acetaminophen/paracetamol ) within 3 day opioid medication within 24 hour . Use selective serotonin reuptake inhibitor ( SSRIs ) , gabapentin , pregabalin ( Lyrica® ) , duloxetine ( Cymbalta® ) within 3 day surgery . Concurrent painful physical condition concurrent surgery may require analgesic treatment ( NSAID opioid ) postsurgical period pain strictly relate surgery , may confound postsurgical assessment ( e.g. , cancer pain , chronic neuropathic pain , concurrent abdominal surgery ) . Current use systemic glucocorticosteroids within 1 month enrollment . Body weight &lt; 50 kilogram ( 110 pound ) body mass index ≥ 35 kg/m2 . Contraindication paincontrol agent plan surgical postsurgical use ( i.e. , fentanyl , morphine , hydromorphone , oxycodone , bupivacaine ) . Administration investigational drug within 30 day 5 elimination halflives investigational drug , whichever longer , prior study drug administration , plan administration another investigational product procedure subject 's participation study . Previous participation liposome bupivacaine study . History , suspect , know addiction abuse illicit drug ( ) , prescription medicine ( ) , alcohol within past 2 year . Uncontrolled anxiety , schizophrenia , psychiatric disorder , opinion Investigator , could interfere study assessment compliance . Current historical evidence clinically significant disease condition , especially cardiovascular neurological condition , opinion Investigator , may increase risk surgery complicate subject 's postsurgical course interfere determination pain intensity relate solely surgery . Significant medical condition ( include widely disseminate metastatic disease ) laboratory result , opinion Investigator , indicate increase vulnerability study drug procedure . Subjects plan receive Entereg® ( alvimopan ) . Subjects receive prophylactic antiemetic plan postsurgical antiemetic give without regard subject 's emesis need .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>liposome bupivacaine</keyword>
	<keyword>posterolateral thoracotomy</keyword>
	<keyword>intercostal nerve block</keyword>
	<keyword>postoperative pain</keyword>
</DOC>